StockData
Inhibitor Therapeutics, Inc. logo

Inhibitor Therapeutics, Inc. (INTI) shareholders

INTIOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 1/30
$0.11+0.00 (+0.09%)

Close on Oct 19, 2026Market cap $19.06MP/E –Yield –

Ownership

Who owns Inhibitor Therapeutics's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Francis E. Odonnell JrChief Executive Officer, Director, 10% owner85,777,06949.36%Aug 4, 2026
James A. McNultyChief Financial Officer46,002,11426.47%Aug 4, 2026
Michelle YanezDirector1,221,2710.70%Aug 4, 2026
Samuel P. Sears JrDirector1,229,5430.71%Aug 4, 2026
Ronald E. OsmanDirector, 10% owner23,554,98513.55%Aug 4, 2026
Michael Allen JermanDirector180,4110.10%Jun 24, 2026
Niraj VasishtDirector200,0000.12%Jun 1, 2026
Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 201210% owner47,104,97027.10%Aug 4, 2026
Robe Capital LLC Black10% owner20,101,05711.57%Aug 4, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
James A. McNulty
Chief Financial Officer
Jul 1, 2026Gift−3,200,000––19,901,057
Niraj Vasisht
Director
May 5, 2026Award+50,000––200,000
Francis E. Odonnell Jr
Chief Executive Officer, Director, 10% owner
May 4, 2026Award+50,000––150,000
Michelle Yanez
Director
May 4, 2026Award+50,000––1,221,271
Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012
10% owner
May 4, 2026Award+50,000––23,614,985
Samuel P. Sears Jr
Director
May 4, 2026Award+50,000––1,229,543
Michael Allen Jerman
Director
May 4, 2026Award+50,000––180,411
Niraj Vasisht
Director
Apr 1, 2025Award+50,000–––
Ronald E. Osman
Director, 10% owner
Apr 1, 2025Award+50,000––23,554,985
Michelle Yanez
Director
Apr 1, 2025Award+50,000––896,271
Michael Allen Jerman
Director
Apr 1, 2025Award+50,000––80,411
Samuel P. Sears Jr
Director
Apr 1, 2025Award+50,000––1,279,543
James A. McNulty
Chief Financial Officer
Dec 2, 2024Gift+1,000,000––1,946,135
Michelle Yanez
Director
Dec 2, 2024Gift+250,000––1,146,271
Michelle Yanez
Director
Apr 1, 2024Award+50,000––896,271
Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012
10% owner
Apr 1, 2024Award+50,000––23,564,985
Samuel P. Sears Jr
Director
Apr 1, 2024Award+50,000––1,129,543
Michael Allen Jerman
Director
Apr 1, 2024Award+50,000––80,411
Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012
10% owner
Aug 11, 2023Award+25,000––23,514,985
James A. McNulty
See Remarks, 10% owner
May 5, 2023Other+398,135––946,135
James A. McNulty
See Remarks, 10% owner
May 5, 2023Other−79,627,069––0
James A. McNulty
See Remarks, 10% owner
May 5, 2023Other+20,101,057––26,101,057
Michelle Yanez
Director
May 5, 2023Other+796,271––800,673
Pharma International Pty Ltd Mayne
10% owner
Jan 15, 2021Other+2,240,488––204,083,227
Pharma International Pty Ltd Mayne
10% owner
Jul 15, 2020Other+3,189,688––201,842,739
W. Mark Watson
Director
Dec 12, 2019Buy+500$0.06$301,054,100
Garrison J. Hasara
CFO and Treasurer
Dec 2, 2019Buy+13,500$0.07$9453,972,544
Pharma International Pty Ltd Mayne
10% owner
Jan 15, 2019Other+362,121––198,653,051
E. Brendan Magrab
Director
Dec 20, 2018Award+65,000$0.08$5.20K65,000
Robert Daniel Martin
Director
Dec 20, 2018Award+60,000$0.08$4.80K116,000
Garrison J. Hasara
CFO and Treasurer
Aug 30, 2018Sale−100,000$0.27$27.00K3,959,044
Pharma Ventures Pty Ltd Mayne
10% owner
Jul 15, 2018Other+184,798––198,290,930
Pharma International Pty Ltd Mayne
10% owner
Dec 19, 2017Buy+600,000$162660.00$97.60B198,106,132
Stefan Cross
Director
Dec 19, 2017Buy−600,000$162660.00$97.60B0
HedgePath, LLC
10% owner
Jun 30, 2017Sale−2,500,000––79,627,069
Nicholas J. Virca
President and CEO
Mar 8, 2017Tax withholding−6,314,219$0.34$2.15M8,727,519
Nicholas J. Virca
President and CEO
Mar 8, 2017Option exercise+15,041,738––15,041,738
Stefan Cross
Director
Mar 8, 2017Option exercise+300,000––600,000
Stefan Cross
Director
Mar 8, 2017Option exercise+300,000––300,000
Richard Dana Ono
Director
Mar 8, 2017Option exercise+300,000––300,000
Richard Dana Ono
Director
Mar 8, 2017Tax withholding−118,800$0.34$40.39K181,200
Richard Dana Ono
Director
Mar 8, 2017Tax withholding−118,800$0.34$40.39K362,400
Richard Dana Ono
Director
Mar 8, 2017Option exercise+300,000––481,200
Richard Dana Ono
Director
Mar 8, 2017Option exercise+150,000––512,400
Richard Dana Ono
Director
Mar 8, 2017Tax withholding−59,400$0.34$20.20K453,000
Garrison J. Hasara
CFO and Treasurer
Mar 8, 2017Tax withholding−1,470,478$0.34$499.96K2,029,522
Garrison J. Hasara
CFO and Treasurer
Mar 8, 2017Option exercise+3,500,000––5,529,522
Garrison J. Hasara
CFO and Treasurer
Mar 8, 2017Tax withholding−1,470,478$0.34$499.96K4,059,044
Garrison J. Hasara
CFO and Treasurer
Mar 8, 2017Option exercise+3,500,000––3,500,000
W. Mark Watson
Director
Mar 8, 2017Tax withholding−79,200$0.34$26.93K553,600
W. Mark Watson
Director
Mar 8, 2017Option exercise+200,000––632,800
W. Mark Watson
Director
Mar 8, 2017Tax withholding−158,400$0.34$53.86K432,800
W. Mark Watson
Director
Mar 8, 2017Option exercise+400,000––591,200
W. Mark Watson
Director
Mar 8, 2017Option exercise+300,000––310,000
W. Mark Watson
Director
Mar 8, 2017Tax withholding−118,800$0.34$40.39K191,200
Pharma International Pty Ltd Mayne
10% owner
Nov 15, 2016Option exercise+4,750,569––192,645,799
Pharma International Pty Ltd Mayne
10% owner
Nov 15, 2016Option exercise+4,860,000––197,506,132
Pharma International Pty Ltd Mayne
10% owner
Nov 15, 2016Option exercise+333––192,646,132
Pharma International Pty Ltd Mayne
10% owner
Nov 4, 2016Option exercise+33,333,000––187,895,230
Pharma International Pty Ltd Mayne
10% owner
Nov 4, 2016Option exercise+5,500,000––154,562,230

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
–
Short volume, 0 days
–
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Inhibitor Therapeutics's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

See a number that looks wrong?